이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aptevo Therapeutics 관리

관리 기준 확인 4/4

Aptevo Therapeutics' CEO는 Marvin White, Aug2016 에 임명되었습니다 의 임기는 7.83 년입니다. 총 연간 보상은 $ 873.45K, 64.7% 로 구성됩니다. 64.7% 급여 및 35.3% 보너스(회사 주식 및 옵션 포함). 는 $ 871.77 가치에 해당하는 회사 주식의 0.038% 직접 소유합니다. 871.77. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 7.8 년입니다.

주요 정보

Marvin White

최고 경영자

US$873.4k

총 보상

CEO 급여 비율	64.7%
CEO 임기	7.8yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	7.8yrs

최근 관리 업데이트

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

CEO 보상 분석

Marvin White 의 보수는 Aptevo Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$873k	US$565k	-US$19m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	US$17m
Dec 31 2022	US$1m	US$565k	US$7m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$6m
Mar 31 2022	n/a	n/a	-US$30m
Dec 31 2021	US$3m	US$565k	-US$29m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$971k	US$498k	-US$31m
Sep 30 2020	n/a	n/a	-US$33m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$974k	US$547k	-US$43m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$1m	US$565k	-US$54m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$35m
Dec 31 2017	US$1m	US$543k	-US$33m

보상 대 시장: Marvin 의 총 보상 ($USD 873.45K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Marvin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Marvin White (62 yo)

7.8yrs

테뉴어

US$873,446

보상

Mr. Marvin L. White has been Independent Director at Emergent BioSolutions Inc. since 2022 and served as its Director since October 1, 2020 until 2022. Mr. White has been the Chief Executive Officer, Presi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Marvin White	President	7.8yrs	US$873.45k	0.038% $ 468.8
Jeffrey Lamothe	Executive VP & COO	1.3yrs	US$741.59k	0.021% $ 260.7
SoYoung Kwon	Senior VP	2.9yrs	US$654.73k	0.014% $ 179.9
Daphne Taylor	Senior VP & CFO	1.3yrs	데이터 없음	0.010% $ 127.8
Dirk Huebner	Chief Medical Officer	2.4yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: APVO 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Marvin White	President	7.8yrs	US$873.45k	0.038% $ 468.8
Daniel Abdun-Nabi	Independent Director	7.8yrs	US$73.21k	0.0068% $ 84.8
Zsolt Harsanyi	Independent Director	7.8yrs	US$93.21k	0.0069% $ 85.6
John Niederhuber	Independent Chairman	7.8yrs	US$88.21k	0.0053% $ 66.4
Barbara Kunz	Independent Director	7.8yrs	US$78.21k	0.0049% $ 60.6
Grady Grant	Independent Director	7.8yrs	US$70.71k	0.0049% $ 60.6

7.8yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: APVO 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.

Aptevo Therapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Insufficient new directors

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Insufficient new directors

Insufficient new directors

Recent updates

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령